Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled dose-escalation study of voclosporin in adolescents with lupus nephritis
MOH_2022-01-11_010540Phase 3Not yet recruiting
- Sponsor
- Aurinia
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of voclosporin in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (4 arms), sponsored by Aurinia. Primary endpoint: Not reported. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
voclosporin
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2022-01-11_010540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-11_010540.